Which medication among dextromethorphan, ceftriaxone (Rocephin), azithromycin, and benzonatate is responsible for causing hemolytic anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ceftriaxone (Rocephin) is the medication causing hemolytic anemia

Among the medications listed, ceftriaxone (Rocephin) is definitively responsible for causing hemolytic anemia, while dextromethorphan, azithromycin, and benzonatate are not associated with this adverse effect.

Evidence from FDA Drug Label

The FDA-approved drug label for Rocephin explicitly warns about hemolytic anemia 1:

  • "An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone for Injection"
  • "Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children"
  • The label specifically instructs: "If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined" 1

Mechanism and Clinical Presentation

Ceftriaxone causes drug-induced immune hemolytic anemia (DIIHA) through an immune-mediated mechanism where drug-dependent antibodies target red blood cells 2, 3, 4.

Key clinical features to recognize:

  • Onset typically occurs 3-5 days after starting therapy 2, 4
  • Presents with: fatigue, pallor, jaundice, dark/wine-colored urine (hemoglobinuria), tachycardia
  • Laboratory findings: rapid hemoglobin drop, positive direct antiglobulin test (DAT), elevated LDH, hemoglobinuria
  • Can progress to life-threatening complications including disseminated intravascular coagulation (DIC), multi-organ failure, and death within hours 3

Recent Case Evidence

Multiple recent case reports confirm ceftriaxone as a significant cause of DIIHA:

  • A 2026 case documented fatal multi-organ failure occurring 3 days post-transfusion, initially misdiagnosed as delayed hemolytic transfusion reaction 2
  • Another 2026 case showed fulminant DIC and death within 8 hours of ceftriaxone administration 3
  • Pediatric cases demonstrate hemoglobin drops from 12.9 to 2.6 g/dL within days, causing hypovolemic shock 5

Critical Diagnostic Pitfall

DIIHA from ceftriaxone can masquerade as a delayed hemolytic transfusion reaction in recently transfused patients 2. The key distinguishing feature is demonstrating ceftriaxone-dependent antibodies through specialized immunohematology testing at reference laboratories.

Immediate Management Algorithm

  1. Immediately discontinue ceftriaxone at first suspicion
  2. Obtain: CBC, reticulocyte count, LDH, haptoglobin, direct antiglobulin test (DAT), urinalysis for hemoglobinuria
  3. Send serum for drug-dependent antibody testing to reference laboratory
  4. Provide supportive care: transfusion support, corticosteroids (methylprednisolone), plasma exchange for severe cases 4
  5. Monitor for DIC and organ dysfunction
  6. Switch to alternative non-cephalosporin antibiotic

The Other Medications

None of the other listed medications are associated with hemolytic anemia:

  • Dextromethorphan: Cough suppressant with no hemolytic anemia association
  • Azithromycin: Macrolide antibiotic associated with GI disturbances, cardiac conduction abnormalities, and hepatotoxicity—but not hemolytic anemia 6
  • Benzonatate: Antitussive with no hemolytic anemia association

The evidence is unequivocal that ceftriaxone is the culprit medication.

References

6
Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2016

Related Questions

Is ceftriaxone (Rocephin) or hydralazine more likely to cause drug‑induced hemolytic anemia?
What are the likely causes of hematuria in a patient who has just completed a course of ceftriaxone, and what diagnostic work‑up should be performed?
Should the weekly low‑molecular‑weight heparin (enoxaparin) be held in an 88‑year‑old patient with non‑resolving pneumonia?
Can clindamycin cause a decrease in hemoglobin?
What is the appropriate evaluation and management for a patient who completed ceftriaxone therapy, was discharged, and returns 10 days later with recurrent symptoms?
What are IgE antibodies, their function, and clinical relevance?
What should the patient do after missing a dental appointment following a recurrent dental infection treated with Augmentin (amoxicillin‑clavulanate) two weeks ago?
What does Stroke unit care class I level A entail for a patient 6 hours after a parieto‑occipital infarct presenting with hemiplegia?
What is the appropriate management of a urinary tract infection in a diabetic patient, including antibiotic selection based on renal function and glycemic control?
Is ceftriaxone (Rocephin) or hydralazine more likely to cause drug‑induced hemolytic anemia?
Which leukemia is associated with four‑leaf‑clover (flower) cells on a peripheral blood smear?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.